Qatar’s cutting-edge healthcare infrastructure, further enhanced by innovative treatments and strong international collaborations, positions the country as a rising destination for medical tourism in the region, according to Aamal Company CEO Rashid bin Ali al-Mansoori.
Speaking to 'Gulf Times', al-Mansoori expressed confidence in Qatar’s capabilities, highlighting its status as having one of the world’s best healthcare systems and the presence of “very advanced hospitals”. He also stressed that Hamad Hospital stands out in the region.
“Healthcare is an important pillar in Qatar’s vision 2030, so we need to be supporting this vision by bringing the best to the Qatar market,” he said, citing the recent introduction of innovative treatments, such as the recently launched obesity drug Wegovy. This, he pointed out, forms part of Aamal’s aim of providing the best in healthcare for the people of Qatar.
“We look at healthcare not only as a trading or for making profit but it is the service and social responsibility of Aamal for its community,” al-Mansoori said. He added that partnerships with international pharmaceutical leaders such as Novo Nordisk, the manufacturer of Wegovy, are crucial not just for accessing new medicines but also for knowledge transfer.
Al-Mansoori said that Aamal’s commitment extends beyond providing medication, but to include public health awareness and prevention. He said the company actively works to educate its staff and the wider community about these diseases, viewing such efforts as fundamental, pre-medical steps that underline the importance of lifestyle and dietary choices.
He said the noticeable increase in general tourism, demonstrated by reports of a crowded airport, also shows that Qatar’s tourism authorities are successfully working on all fronts to attract more visitors and diversify the nation’s economy.
Rashid bin Ali al-Mansoori
